Guardian Asset Advisors’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-2,637
Closed -$229K – 127
2026
Q1
$229K Buy
+2,637
New +$231K 0.13% 98
2025
Q2
– Sell
-2,946
Closed -$208K – 106
2025
Q1
$208K Sell
2,946
-568
-16% -$39.5K 0.14% 99
2024
Q4
$231K Sell
3,514
-157
-4% -$10.8K 0.15% 95
2024
Q3
$259K Sell
3,671
-169
-4% -$11.8K 0.18% 90
2024
Q2
$255K Sell
3,840
-115
-3% -$7.54K 0.19% 88
2024
Q1
$269K Buy
3,955
+160
+4% +$10.6K 0.22% 86
2023
Q4
$235K Buy
+3,795
New +$223K 0.22% 87

Other funds holding IHE

Guardian Asset Advisors's IHE Position: Q2 2026 in Review

Guardian Asset Advisors sold out of iShares US Pharmaceuticals ETF (IHE) in Q2 2026, closing a stake of 2,637 shares — an estimated $229K sold.

Guardian Asset Advisors first reported a position in IHE in Q4 2023 and held it in 7 quarters. The position peaked at $269K in Q1 2024. 209 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

  • Guardian Asset Advisors reported no remaining iShares US Pharmaceuticals ETF position as of Q2 2026 after selling out during the quarter.
  • Guardian Asset Advisors sold 2,637 iShares US Pharmaceuticals ETF shares in Q2 2026, an estimated $229K.
  • Guardian Asset Advisors first reported a position in iShares US Pharmaceuticals ETF in Q4 2023 and held it in 7 quarters.
  • Guardian Asset Advisors's iShares US Pharmaceuticals ETF position peaked at $269K in Q1 2024.
  • 209 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Guardian Asset Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.